Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

18. juni 2021 opdateret af: Dr Sachin Punatar, Tata Memorial Centre

Pilot Study of Leflunomide as First Line Therapy for Musculoskeletal GVHD

Graft versus host disease (GVHD) is a well-known complication of allogeneic transplant. In GVHD, the cells of the donor attack the patient's tissues and cause damage. It can affect any organ or system of the body. In a proportion of patients, it affects the joints and muscles. This is known as musculoskeletal GVHD. The standard treatment of musculoskeletal GVHD is steroids. However, these are usually needed for prolonged periods, and cause a large number of additional problems in transplant patients.

Leflunomide is a drug which has been used for several years in diseases like rheumatoid arthritis (RA). RA is an auto-immune disorder. The biological mechanisms underlying RA and musculoskeletal GVHD are quite similar. Hence it is likely that leflunomide may work in musculoskeletal GVHD also. The investigator have previously used leflunomide in a few patients with musculoskeletal GVHD and have found it to be extremely effective. Also, it was very safe (unlike steroids). Yet another advantage is that it is fairly cheap.

The purpose of the current study is to study the efficacy and safety of leflunomide in patients with musculoskeletal GVHD in a prospective way.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The curative potential of allogeneic hematopoietic stem cell transplantation (allo-HCT) is hampered by acute and chronic graft-versus-host disease (GVHD). Although chronic GVHD (cGVHD) can affect any organ / system in the body, commonly affected are skin, oral cavity, eyes, liver, joints and fascia, and lungs. Involvement of these can occur alone or concurrently, and these lead to a significant negative impact on the patient's quality of life. Musculoskeletal involvement in chronic GVHD (mGVHD) can have varied presentations like fasciitis, myositis, arthritis, etc. The basic pathogenesis of mGvHD closely mimics autoimmune disorders like rheumatoid arthritis, systemic sclerosis, systemic lupus, etc.

The treatment goals of mGvHD include improvement or stabilisation of manifestations, limitation of long-term treatment related toxicities, improvement in functional capacity and quality of life. Corticosteroids, the standard frontline treatment, are typically administered for a median of 2 to 3years, leading to substantial morbidity. An effort to decrease corticosteroid doses has led to their use in combination with other drugs, such as cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, rituximab, etanercept, ruxolotinib, imatinib, ibrutinib, ECP (extra corporeal photopheresis), methotrexate etc, in frontline or second-line settings. All these drugs have been used with far and few responses but with significant treatment related toxicity and costs. As far as musculoskeletal GVHD is concerned, the British guidelines recommend corticosteroids as first line treatment and rituximab as second line option. However, the morbidity associated with long term steroid use warrants a quest for use of non-steroid therapies to be used in 1st line setting for chronic GVHD.

Leflunomide has been used in rheumatoid arthritis. At our centre, the investigator have previously used leflunomide for patients with musculoskeletal GVHD and found it to be effective and safe. Leflunomide is relatively cheap and potentially more effective compared to other more expensive alternatives. If proven to be effective in a larger cohort of patients, this drug could become the standard first line agent in this setting.

With this, the investigator have planned to carry out this study to assess the efficacy of leflunomide in musculoskeletal GVHD post allogeneic stem cell transplant.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

10

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Indien
    • Maharashtra
      • Navi Mumbai, Maharashtra, Indien, 410210
        • Rekruttering
        • Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 sekund til 65 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Willing to give written informed consent
  2. Patients diagnosed with musculoskeletal mGvHD based on 2014 NIH consensus criteria (with diagnosis confirmed by biopsy only if clinically required).
  3. Willing and able to comply with all study requirements, including treatment, and periodic assessments.

Exclusion Criteria:

  1. Patients with known hypersensitivity to leflunomide especially previous Steven Johnson syndrome, toxic epidermal necrolysis after leflunomide.
  2. Pregnant females
  3. Patients with musculoskeletal manifestations explained by other potential causes ( (drugs, trauma, etc).
  4. Patients with calculated glomerular filtration rate (GFR) <30ml/min at the time of screening.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Leflunomide Arm
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
Medicin: Leflunomide tablet

Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.

The dosing for children will be as follows:

  1. <20 kg - 100 mg x 1 day followed by 10 mg every alternate day
  2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily
  3. >40 kg - Usual adult dose.

This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.

Andre navne:
  • Leflunomid

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall objective response rate
Tidsramme: Through study completion, an average of 2 years
Response will be defined as per the NIH 2014 consensus response criteria working group for mGvHD.
Through study completion, an average of 2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to response
Tidsramme: From date of start of leflunomide to date of first documented response, assessed up to 2 Years
The time required to achieve complete or partial response after treatment.
From date of start of leflunomide to date of first documented response, assessed up to 2 Years
Time to best response
Tidsramme: From date of start of leflunomide to date of documented best response, assessed up to 2 Years
Time to best response will be recorded.
From date of start of leflunomide to date of documented best response, assessed up to 2 Years
Duration of response
Tidsramme: From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
The duration of response will be calculated from the time of onset of objective response after initiation of treatment with leflunomide until the end of the follow-up, GVHD relapse, the development of new or the deterioration of pre-existing mGVHD symptoms, or the reinstitution of any additional agents to control the disease.
From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
Relapse rate
Tidsramme: Through study completion, an average of 2 years
Relapse rate of mGVHD after stopping leflunomide will be recorded.
Through study completion, an average of 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Tata Memorial Centre

Efterforskere

  • Ledende efterforsker: Sachin Punatar, MD, DM, Tata Memorial Centre

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Forventet)

15. juni 2021

Primær færdiggørelse (Forventet)

9. april 2023

Studieafslutning (Forventet)

9. april 2023

Datoer for studieregistrering

Først indsendt

5. juni 2021

Først indsendt, der opfyldte QC-kriterier

18. juni 2021

Først opslået (Faktiske)

21. juni 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. juni 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. juni 2021

Sidst verificeret

1. juni 2021

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 900643
  • CTRI/2021/04/033214 (Registry Identifier: Clinical Trials Registry- India (CTRI))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Muskuloskeletal sygdom Andet

  • Children's Hospital Medical Center, Cincinnati
    Rekruttering
    Topunktsdiskrimination (TPD)
    Lændesmerter | Kronisk udbredt smerte | Fibromyalgi | Kompleks regionalt smertesyndrom (CRPS) | Ehlers-Danlos syndrom (EDS) | Amplified Musculoskeletal Pain Syndrome (AMPS)
    Forenede Stater

Kliniske forsøg med Leflunomide tablet

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Montenegro

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner